Last Updated: November 16, 2026

Details for Patent: 10,548,875

« Back to Dashboard


Which drugs does patent 10,548,875 protect, and when does it expire?

Patent 10,548,875 protects QBREXZA and is included in one NDA.

This patent has twenty-nine patent family members in thirteen countries.

Summary for Patent: 10,548,875
Title:Glycopyrrolate salts
Abstract:Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.
Inventor(s):John Allan STATLER, Anthony Adrian SHAW, Delphine Caroline Imbert, Jennifer Leigh NELSON, Patricia Andres, Lisa Lynn McQueen, Stephan Xander Mattheus BOERRIGTER, Jon Gordon Selbo, Mark Christopher Andres
Assignee: Journey Medical Corp
Application Number:US16/235,120
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,548,875
Patent Claim Types:
see list of patent claims
Use; Formulation;
Patent landscape, scope, and claims:

US Patent 10,548,875: Claim Scope, Qbrexza Coverage, and Glycopyrronium Tosylate Patent Landscape

US Patent 10,548,875 covers glycopyrronium tosylate, also known as glycopyrronium bromide? No. The claimed active ingredient is the tosylate salt of glycopyrronium, the active pharmaceutical ingredient in Qbrexza, a topical product approved for primary axillary hyperhidrosis. The patent has four principal protection layers: the racemic glycopyrronium tosylate compound, liquid formulations, polypropylene absorbent pads, and topical treatment methods.

The strongest commercial relevance is the combination of a glycopyrronium tosylate solution with ethanol, acidic pH, and a single-use nonwoven polypropylene pad. Those limitations closely track the Qbrexza delivery format and may create meaningful formulation and packaging barriers even where a competing product uses the same active ingredient.

What drug does US Patent 10,548,875 protect?

The patent claims a racemic mixture of two stereochemical forms of 3-substituted 1,1-dimethylpyrrolidinium tosylate. This compound is glycopyrronium tosylate, commonly used in topical anticholinergic formulations for hyperhidrosis.

Patent element Claimed subject matter Commercial relevance
Active ingredient Racemic glycopyrronium 4-methylbenzenesulfonate Active in Qbrexza
Dosage form Pharmaceutically acceptable solution Liquid topical product
Delivery system Absorbent pad, including polypropylene Premoistened topical cloth
Solvent Ethanol Supports rapid drying and delivery
Concentration 1% to 6% in claims 4 and 11 Includes 2.4% Qbrexza strength
pH 3.5 to 5.5, with narrower ranges of 4.0 to 4.7 Formulation stability and tolerability
Treatment use Topical treatment of hyperhidrosis Axilla, hands, feet, groin, face, back, abdomen
Packaging Sealed pouch, including aluminum-foil laminate Single-use product stability

FDA approved Qbrexza in 2018 as a topical cloth containing 2.4% glycopyrronium tosylate for primary axillary hyperhidrosis in adults and pediatric patients aged 9 years and older.[1]

How many patent claims are in US Patent 10,548,875?

The supplied claim set contains 27 claims. Claims 1, 2, 9, and 12 are independent. The remaining claims add narrower formulation, pad, packaging, anatomical-site, and process limitations.

Claim group Claims Protection focus
Compound 1 Racemic glycopyrronium tosylate
Absorbent pad 2-8 Solution-loaded pad, polypropylene, pouch and foil laminate
Solution 9-11 Glycopyrronium tosylate solution with additive, ethanol, concentration and pH
Treatment method 12-27 Topical treatment, body sites, pad administration, ethanol, pH, appearance

The independent claims have different infringement targets. Claim 1 is directed to the composition itself. Claim 9 is directed to a solution. Claim 12 is directed to the act of treating hyperhidrosis. Claim 2 is directed to a physical article containing the solution.

What does claim 1 cover?

Claim 1 covers the racemic mixture of two specifically identified stereoisomeric glycopyrronium tosylate compounds. The claim is narrow in chemical identity but broad in physical presentation. It does not require a particular concentration, solvent, dosage form, pH, packaging configuration, or therapeutic indication.

A product may fall within claim 1 if it contains the claimed racemic glycopyrronium tosylate, even if it is:

  • A bulk active pharmaceutical ingredient;
  • A solution;
  • A cream, gel, spray, or wipe;
  • Packaged in a container other than a foil pouch; or
  • Marketed for an indication other than hyperhidrosis.

The claim does not expressly require a 50:50 stereoisomer ratio by analytical measurement. The term “racemic mixture” ordinarily indicates an approximately equimolar mixture, but the enforceable scope would depend on the patent specification, prosecution history, and claim-construction record.

Potential design-around approaches include using a different counterion, an enantiomer rather than the claimed racemate, or a chemically distinct glycopyrronium formulation. Each approach would require separate analysis because a product could avoid literal infringement of claim 1 while still implicating formulation or method claims.

What formulations are protected by claims 9 through 11?

Claim 9 covers a pharmaceutically acceptable solution containing the claimed racemic glycopyrronium tosylate and at least one pharmaceutically acceptable additive. Claim 10 narrows the additive to ethanol. Claim 11 requires both a concentration between 1% and 6% by weight and a pH between 3.5 and 5.5.

The formulation claims are broader than the specific Qbrexza formulation in several respects. Claim 9 does not require ethanol, a specific pH, a concentration range, or a particular solvent system. It can potentially cover aqueous, hydroalcoholic, or other pharmaceutically acceptable liquid vehicles, subject to the claim language and specification.

Claim 11 is commercially significant because the 1% to 6% range includes the 2.4% strength used in Qbrexza.[1] The pH limitation also captures the acidic formulation disclosed in the later treatment claims.

Formulation claim hierarchy

Claim Required limitations
9 Glycopyrronium tosylate racemate, solution, at least one pharmaceutically acceptable additive
10 Claim 9 plus ethanol
11 Claim 9 plus 1%-6% active and pH 3.5-5.5

A competing product using glycopyrronium tosylate at 2.4% in an ethanol-containing solution at pH 4.3 would present a substantial literal-infringement risk under claim 11, assuming the product contains the claimed racemic salt.

What absorbent pads are protected by claims 2 through 8?

Claims 2 through 8 protect a pad containing the glycopyrronium tosylate solution. The claims are directed to both the chemical loading and the physical delivery article.

The main limitations are:

  1. A pharmaceutically acceptable solution containing the racemic active ingredient;
  2. At least one pharmaceutically acceptable additive;
  3. Optional ethanol;
  4. Active concentration of 1% to 6%;
  5. Solution pH of 3.5 to 5.5;
  6. Polypropylene pad material;
  7. Nonwoven 100% polypropylene;
  8. Sealed pouch;
  9. Aluminum foil as a pouch layer.

Claims 5 and 6 narrow the pad material. Claim 5 requires polypropylene, while claim 6 requires nonwoven 100% polypropylene. A cellulose, polyester, rayon, cotton, or mixed-fiber wipe may avoid those specific limitations, although it could still implicate the broader solution claims or treatment-method claims.

Claim 7 requires sealing in a pouch. Claim 8 narrows the pouch to a laminate containing aluminum foil. These packaging limitations are important for products that depend on controlled moisture retention, solvent containment, and protection from light or oxygen.

Qbrexza relevance

Qbrexza is supplied as a single-use cloth impregnated with glycopyrronium tosylate solution. The product label identifies a premoistened cloth dosage form and directs patients to wipe the cloth over each underarm once daily.[1] To the extent the commercial cloth uses the claimed polypropylene substrate, ethanol concentration, acidic pH, and foil-laminate packaging, it may practice multiple dependent claims.

The claims do not require the product to be called a “cloth,” “wipe,” or “towelette.” The functional and structural limitations control.

What methods of treating hyperhidrosis are protected?

Claim 12 covers topical administration of a therapeutically effective amount of the claimed glycopyrronium tosylate solution to mammalian skin. Claim 13 limits the mammal to a human.

Claims 14 through 17 identify treatment sites:

  • Axilla;
  • Hands;
  • Feet;
  • Groin;
  • Face;
  • Back; and
  • Abdomen.

Claims 18 and 19 require administration with an absorbent pad containing the absorbed solution. Claims 20 through 27 add ethanol, ethanol concentration, pH, and visual appearance limitations.

Claim Method limitation
12 Topical treatment of hyperhidrosis in a mammal
13 Human patient
14 Axillary administration
15 Hand administration
16 Foot administration
17 Groin, face, back, or abdomen
18 Administration with an absorbent pad
19 Axillary treatment with an absorbent pad
20-22 Ethanol-containing solution
23 57%-59.5% dehydrated ethanol
24 pH 4.0-5.0
25 pH 4.0-4.7
26 pH 4.1-4.6
27 Clear, colorless, or pale-yellow solution at 25°C and pH 4.0-5.0

The method claims can be relevant even where a supplier does not manufacture the cloth. In a generic or competing-product case, liability analysis would examine the product labeling, instructions for use, distribution conduct, and whether the labeled use encourages practice of the claimed method.

How narrow are claims 23 through 27?

Claims 23 through 27 are narrow formulation and method claims. They require claim 22 as an antecedent, which in turn requires:

  • Treatment under claim 18;
  • Ethanol under claim 20 or claim 21; and
  • An absorbent-pad administration format.

Claim 23 requires approximately 57% to 59.5% dehydrated ethanol by weight. Claims 24 through 26 progressively narrow the pH range. Claim 27 adds appearance and temperature limitations.

These claims are easier to design around than claims 9, 11, or 12. A competing product may avoid them by using:

  • A different ethanol concentration;
  • A pH outside the claimed range;
  • A non-pad delivery format;
  • A formulation that is not clear, colorless, or pale yellow; or
  • A different active ingredient or salt.

Avoiding a narrow dependent claim does not avoid the broader independent claims. For example, a product with a glycopyrronium tosylate solution but without the claimed ethanol level could still raise issues under claim 9 or claim 12.

What is the FDA and Orange Book status of the patent?

Qbrexza is an FDA-approved prescription topical product for primary axillary hyperhidrosis.[1] The regulatory product is a drug-device-like delivery presentation in which the active solution is supplied on a single-use cloth.

Patent listing in the FDA Orange Book is distinct from patent validity and infringement. A listed patent may be challenged through an abbreviated new drug application certification, including a Paragraph IV certification, but the Orange Book record must be reviewed for the current listing status, patent-use code, and listed expiration date.[2]

The supplied claim set alone does not establish:

  • Whether US 10,548,875 is currently listed in the Orange Book;
  • The exact Orange Book expiration date;
  • Whether pediatric exclusivity affects the listed date;
  • Whether patent term adjustment or a terminal disclaimer applies;
  • Whether a Paragraph IV certification has been filed against it; or
  • Whether litigation has triggered a 30-month stay.

The principal FDA exclusivity period for Qbrexza was separate from patent protection. FDA approval in 2018 provided regulatory exclusivity under the applicable new-drug framework, while patent rights operate independently under the Patent Act.[1][3]

When does US Patent 10,548,875 lose exclusivity?

A precise expiration date requires the patent’s earliest effective nonprovisional priority date, patent term adjustment, terminal disclaimer status, and any patent term extension. The ordinary rule is a term of 20 years from the earliest effective nonprovisional US filing date, subject to statutory adjustments under 35 U.S.C. §§ 154 and 156.[4]

The issue date, January 28, 2020, does not determine expiration. Patent term adjustment can extend the ordinary term, while a terminal disclaimer can limit the term to that of another patent. Patent term extension for regulatory review is possible only if statutory requirements are met and the patent covers the approved product or an approved method of use.[4]

For transaction and launch planning, the relevant dates are the expiration dates of the entire patent family, not only US 10,548,875. Earlier composition or method patents may create blocking rights, and later continuation patents may preserve narrower formulation or use claims after the parent patent expires.

Which companies are challenging glycopyrronium tosylate exclusivity?

The commercial product is Qbrexza, originally developed by Dermira and later commercialized under Almirall following Almirall’s acquisition of Dermira.[5] Public information available from the supplied record does not establish a current Paragraph IV challenger, ANDA filer, settlement agreement, or active litigation against US 10,548,875.

A generic entrant would likely assess several separate barriers:

Barrier Risk to entrant
Compound claim High if the same racemic glycopyrronium tosylate is used
Solution claim High if the product uses a comparable liquid formulation
Pad claim High if the product uses polypropylene cloth technology
Method claim High for labeling directed to topical hyperhidrosis treatment
Packaging claim Moderate because pouch materials can be redesigned
Narrow ethanol and pH claims Moderate to high depending on formulation design
FDA substitution Depends on ANDA requirements and reference-product presentation

A non-infringing generic strategy could use a different dosage form, a different counterion, a different substrate, or a formulation outside the concentration and pH ranges. Those changes could create pharmaceutical equivalence, stability, usability, or FDA development issues.

How strong is the patent estate for Qbrexza?

US 10,548,875 has a commercially coherent claim architecture because it covers the active ingredient, the solution, the cloth, and the treatment method. Its strongest practical claims are likely:

  1. Claim 1, if the competitor uses the same glycopyrronium tosylate racemate;
  2. Claim 9, because it broadly covers a solution with a pharmaceutically acceptable additive;
  3. Claim 11, where concentration and pH overlap;
  4. Claim 12, where labeling directs topical treatment of hyperhidrosis; and
  5. Claims 18 and 19, where the competitor uses an impregnated pad.

The narrowest claims, including claims 23 through 27, provide less standalone coverage but may strengthen enforcement against a product closely copied from the reference product.

The estate’s overall strength depends on prosecution history, written-description support, enablement, definiteness, double-patenting exposure, prior-art disclosures involving glycopyrrolate and topical anticholinergics, and the status of related continuation patents. The claim set indicates strong product-specific coverage but does not by itself establish validity.

What licensing and litigation issues affect the patent?

Dermira’s acquisition by Almirall transferred the commercial asset and associated intellectual-property interests into Almirall’s portfolio.[5] The supplied record does not identify a separate patent license, royalty-bearing collaboration, Paragraph IV settlement, or active district-court case specific to US 10,548,875.

For diligence, the key legal documents are:

  • The complete US 10,548,875 prosecution history;
  • Related continuation and divisional applications;
  • Current USPTO assignment records;
  • FDA Orange Book listing data;
  • Any ANDA notice letters;
  • District-court complaints and docket entries;
  • Inter partes review or post-grant review records; and
  • Any settlement or license agreement disclosed in SEC filings.

What generic launch scenarios exist?

A generic launch could follow several paths.

Same active ingredient and same cloth

This is the highest-risk route. A product using racemic glycopyrronium tosylate in a 1%-6% solution, ethanol, acidic pH, polypropylene cloth, and foil-laminate pouch could implicate most of the claim groups.

Same active ingredient, different dosage form

A bottle, spray, pump, gel, or cream could avoid the pad claims. It would still face claim 1, claim 9, and method claim 12 if it uses the claimed racemic salt and is labeled for hyperhidrosis.

Different pad material

A non-polypropylene substrate could avoid claims 5 and 6. It would not necessarily avoid claim 2, claim 9, or the method claims.

Different salt or stereochemical composition

A different counterion or stereochemically distinct active could avoid claim 1, but the alternative must be pharmaceutically viable and FDA-acceptable. A salt change can affect absorption, stability, irritation, drying time, and equivalence.

Different concentration or pH

This may avoid claims 4, 11, and 24 through 27. It does not necessarily avoid the broader solution and method claims.

Key Takeaways

  • US 10,548,875 covers racemic glycopyrronium tosylate and multiple commercial implementations.
  • The patent claims solutions, polypropylene absorbent pads, foil-laminate pouches, and topical hyperhidrosis treatment methods.
  • Qbrexza’s 2.4% glycopyrronium tosylate cloth falls within the central commercial profile addressed by the claims.
  • Claim 1 is the principal active-ingredient claim.
  • Claims 9 and 12 provide broad formulation and treatment coverage.
  • Claims 23 through 27 are narrower and easier to design around.
  • A generic using the same active ingredient may face compound, formulation, method-of-use, and delivery-system risks simultaneously.
  • The supplied record does not establish the current Orange Book listing, exact patent expiration date, Paragraph IV activity, litigation status, or settlement history.
  • Patent expiration must be calculated from the effective filing date and adjusted for patent term adjustment, terminal disclaimers, and any patent term extension.

FAQs

Does US Patent 10,548,875 cover glycopyrrolate tablets?

No. The supplied claims focus on racemic glycopyrronium tosylate, liquid topical solutions, absorbent pads, and topical treatment of hyperhidrosis. They do not expressly cover oral glycopyrrolate tablets.

Can a competitor avoid the patent by using a spray instead of a cloth?

A spray may avoid the absorbent-pad claims. It could still implicate claim 1, claim 9, and claim 12 if it contains the claimed racemic glycopyrronium tosylate and is labeled for topical hyperhidrosis treatment.

Does the patent cover palmoplantar hyperhidrosis?

Claims 15 and 16 expressly identify the hands and feet. The method claims therefore extend beyond axillary treatment if the other limitations are met.

Is ethanol mandatory under the patent?

No. Ethanol is required only in narrower claims. Claims 9 and 12 do not universally require ethanol, while claims 10, 20, 21, 22, and later dependent claims do.

Does a different pouch material avoid the patent?

A pouch without aluminum foil may avoid claim 8. It would not necessarily avoid the broader pad, solution, compound, or method claims.

References

  1. U.S. Food and Drug Administration. (2018). Qbrexza (glycopyrronium) topical cloth prescribing information.
  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  3. U.S. Food and Drug Administration. (2024). FDA regulatory exclusivity and patent information for approved drug products.
  4. United States Code. (2024). 35 U.S.C. §§ 154-156: Patent term and patent term extension.
  5. Almirall, S.A. (2019). Almirall completes acquisition of Dermira.
  6. United States Patent and Trademark Office. (2020). U.S. Patent No. 10,548,875.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,548,875

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Journey QBREXZA glycopyrronium tosylate CLOTH;TOPICAL 210361-001 Jun 28, 2018 RX Yes Yes 10,548,875 ⤷  Start Trial Y Y TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,548,875

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014223172 ⤷  Start Trial
Australia 2016269524 ⤷  Start Trial
Canada 2902795 ⤷  Start Trial
China 105026369 ⤷  Start Trial
European Patent Office 2961734 ⤷  Start Trial
European Patent Office 3473615 ⤷  Start Trial
European Patent Office 3842419 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.